1. Home
  2. LTRN vs MDCX Comparison

LTRN vs MDCX Comparison

Compare LTRN & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$0.46

Market Cap

10.0M

Sector

Health Care

ML Signal

HOLD

Logo Medicus Pharma Ltd.

MDCX

Medicus Pharma Ltd.

SELL

Current Price

$1.80

Market Cap

10.9M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
LTRN
MDCX
Founded
2013
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.0M
10.9M
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
LTRN
MDCX
Price
$0.46
$1.80
Analyst Decision
Strong Buy
Buy
Analyst Count
2
3
Target Price
$17.50
★ $32.50
AVG Volume (30 Days)
★ 218.7K
53.9K
Earning Date
11-27-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 18.65
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$1.63
52 Week High
$4.34
$115.50

Technical Indicators

Market Signals
Indicator
LTRN
MDCX
Relative Strength Index (RSI) 26.16 25.31
Support Level N/A N/A
Resistance Level $0.84 $2.16
Average True Range (ATR) 0.10 0.28
MACD 0.01 0.22
Stochastic Oscillator 2.47 9.92

Price Performance

Historical Comparison
LTRN
MDCX

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

About MDCX Medicus Pharma Ltd.

Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.

Share on Social Networks: